BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1375@pharmaconomics
DTSTAMP:20260707T031035Z
DTSTART;VALUE=DATE:20260630
DTEND;VALUE=DATE:20260701
SUMMARY:BLTE Phase 2 — tinlarebant
DESCRIPTION:Phase 2 trial results for tinlarebant in Stargardt disease type 1 (STGD1) are due Jun 30\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1889109/000110465926006814/tm264022d1_ex99-1.htm\n\nTrack it: https://pharmaconomics.com/e/1375
URL:https://pharmaconomics.com/e/1375
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:BLTE catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR